Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children - Nolan, Terry; Bravo, Lulu; Ceballos, Ana; Mitha, Essack; Gray, Glenda; Quiambao, Beatriz; Patel, Sanjay S.; Bizjajeva, Svetlana; Bock, Hans; Nazaire-Bermal, Nancy; Forleo-Neto, Eduardo; Cioppa, Giovanni Della; et al. (Vaccine, 2014)
Keywords: (www.clinicaltrials.gov): NCT01346592; Adjuvant; Adjuvants, Immunologic - administration & dosage; Age; Allergy and Immunology; antibodies; Antibodies, Viral - blood; Antibody Formation; Applied microbiology; Biological and medical sciences; Child, Preschool; Children; Female; Fluad; Fundamental and applied biological sciences. Psychology; hemagglutination; Hemagglutination Inhibition Tests; Humans; Immunogenicity; Infant; Infants; Infections; Influenza; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza vaccine; Influenza Vaccines - administration & dosage; Influenza Vaccines - therapeutic use; Influenza, Human - prevention & control; Male; MF59; Microbiology; Polysorbates - administration & dosage; seroconversion; Single-Blind Method; Squalene - administration & dosage; subunit vaccines; vaccination; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vaccines, Subunit - administration & dosage; Vaccines, Subunit - therapeutic use; Viral infections; virion; TIV; HI; AE; CI; (www.clinicaltrials.gov): NCT01346592; aTIV; GMT; PPS; MF59; FAS; Adjuvant; Children; Influenza vaccine; Fluad; full analysis set; hemagglutination inhibition; trivalent influenza vaccine; adverse event; adjuvanted trivalent influenza vaccine; geometric mean titer; per protocol set; confidence interval; Human; Immune response; Infant; Vaccine; Strain; Infection; Viral disease; Immunological adjuvant; Influenza A; Child; Humoral immunity; Fluad(®)